Monday 5 July 2021

Moving Away From Animal Testing: The Case Against The Biological Reactivity Test



 

While some animal testing may, in special circumstances, continue to have a need for the determination of safety in pharmaceuticals, strides are being made in replacing many animal tests with laboratory tests. One such area where progress has been made, and where further action is required, is with the case of the general test for toxic products. While this test is described differently in different compendia, it has the same aim: to determine if mice and guinea pigs die once administered with a pharmaceutical product. Such is the crude nature of the test; it can be argued that if this doubt exists the manufacturer of the product should not be in the business of making medicines in the first place.

 

The test in question is the Biological Reactivity Test (also referred to as: General Safety Test, Abnormal Toxicity Test, or the Innocuity Test) is a test for the detection of extraneous toxic contaminants which is sometimes undertaken for biological products intended for administration to humans. This article sets out the case for its final elimination.

 

 

Sandle, T. (2021) Moving Away From Animal Testing: The Case Against The Biological Reactivity Test, IVT Network, at: https://www.ivtnetwork.com/article/moving-away-animal-testing-case-against-biological-reactivity-test


 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers